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Abstract
Fungal secondary metabolites (SMs) are an important source of medically valuable compounds.
Genome projects have revealed that fungi have many SM biosynthetic gene clusters that are not
normally expressed. To access these potentially valuable, cryptic clusters, we have developed a
heterologous expression system in Aspergillus nidulans. We have developed an efficient system
for amplifying genes from a target fungus, placing them under control of a regulatable promoter,
transferring them into A. nidulans and expressing them. We have validated this system by
expressing non-reducing polyketide synthases of Aspergillus terreus and additional genes required
for compound production and release. We have obtained compound production and release from
six of these NR-PKSs and have identified the products. To demonstrate that the procedure allows
transfer and expression of entire secondary metabolite biosynthetic pathways, we have expressed
all the genes of a silent A. terreus cluster and demonstrate that it produces asperfuranone. Further,
by expressing the genes of this pathway in various combinations, we have clarified the
asperfuranone biosynthetic pathway. We have also developed procedures for deleting entire A.
nidulans SM clusters. This allows us to remove clusters that might interfere with analyses of
heterologously expressed genes and to eliminate unwanted toxins.
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Fungal secondary metabolites (SMs) have biological activities that make them a rich source
of medically useful compounds.1–4 Sequencing of fungal genomes has revealed that many
fungi contain large numbers of genes involved in secondary metabolism and that the genes
of individual SM biosynthetic pathways are clustered together.3, 5–7 The number of SM
biosynthetic clusters is generally much larger than the number of SMs known to be
produced by the organism3 because the majority of fungal SM clusters are silent under most
conditions. There is relatively little overlap in SM clusters even among closely related
fungi,3, 5 indicating that fungi, collectively, have the ability to produce an extraordinary
number of novel compounds of potential medical value. Scores, if not hundreds, of fungal
genomes will be sequenced in coming years and the SM gene clusters within them will
constitute a remarkable medical resource if they can be accessed efficiently.
Perhaps less obviously, identifying and obtaining production of early intermediates in fungal
SM pathways is also extremely valuable. They promise to be excellent starting points for
combinatorial chemistry to produce compounds of potential medical value8 because they
occupy a wider chemical space than synthetic combinatorial libraries and they are more
drug-like.9–11 Early intermediates in polyketide biosynthetic pathways in particular offer, in
principle, a platform for synthetic chemistry (medicinal and non-medicinal) that is
sustainable and efficient. For example, Somoza et al. recently reported the synthesis of
lipoxygenase inhibitors in a very small number of steps from an azaphilone intermediate
obtained by reengineering a biosynthetic pathway of A. nidulans.12 To realize the potential
of fungal secondary metabolites, it is important to be able to identify the products of fungal
biosynthetic pathways and intermediates in those pathways, particularly the early
intermediates released from polyketide synthases (PKSs) and non-ribosomal peptide
synthetases (NRPSs).
For the few species with good molecular genetic systems, progress is being made in using
molecular genetic tools to up-regulate cryptic clusters, determine the products of the clusters
and decipher the biosynthetic pathways encoded by the clusters.13, 14 Most fungi, however,
have poor or nonexistent molecular genetic systems, and this approach is not feasible.
A substantial number of SM gene clusters are regulated, at least in part, at the chromatin
level15 and one useful approach for obtaining SM production from fungi without molecular
genetic systems is to treat them with compounds that inhibit histone deacetylases or methyl
transferases. These alter acetylation or methylation of histones resulting in alteration of
chromatin packing and can lead to expression of SMs from cryptic clusters.16–20 This
approach is often called chemical epigenetics. While the approach is useful in eliciting
production of compounds it is limited in at least two important ways. First, only a portion of
SM pathways are activated by this approach20 and second, this approach, unlike genetic
approaches, doesn’t facilitate the production of useful intermediates or the deciphering of
the biosynthetic pathways for the compounds produced.
Another solution is to develop heterologous expression systems. There has been some
success in heterologous expression of fungal genes in other fungi,13, 14, 21–29 but in each
case a great deal of work was required to obtain expression of one or a few genes.
We have taken two major steps toward the development of the model ascomycete
Aspergillus nidulans as a system for heterologous expression of fungal SMs. First, we have
developed efficient procedures for deleting entire SM gene clusters to prevent production of
toxic or otherwise unwanted compounds. Second, we have developed a rapid, robust and
efficient approach, using fusion PCR to amplify genes from a target fungus, place them
under the control of the regulatable alcA promoter [alcA(p)]30, 31 (Table 1) and transfer
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them into A. nidulans. The approach includes marker recycling so that an unlimited number
of genes can potentially be transferred into a single strain without running out of selectable
markers. We have used this approach to transfer all of the non-reducing polyketide synthase
(NR-PKS) genes of Aspergillus terreus into A. nidulans along with additional genes required
for production or release of the NR-PKS products. This has allowed us to isolate and
identify the products of six A. terreus NR-PKS genes. To determine if it is practical to use
this approach to express an entire SM pathway, we have transferred all the genes of a
putative A. terreus azaphilone biosynthetic pathway into A. nidulans. We find that it
produces asperfuranone, and we have obtained useful yields of this compound. The ability to
express genes of this pathway in various combinations in A. nidulans has allowed us to
analyze the asperfuranone biosynthetic pathway and improve our understanding of
asperfuranone biosynthesis.
Results and Discussion
Deletion of entire A. nidulans SM gene clusters
An important step in developing A. nidulans as a heterologous expression system is to
eliminate production of the most abundant A. nidulans SMs to reduce the SM background
and facilitate detection and purification of the products of heterologously expressed clusters.
This may also reduce competition for substrates such as malonyl-CoA, and enhance the
yield of heterologously expressed SMs. While deleting a key gene in a pathway can
eliminate production of the final product of the pathway, other pathway genes will still be
expressed and may modify intermediates or final products of heterologously expressed gene
clusters. We consequently developed approaches to delete entire SM clusters.
Our first strategy was to try to replace an entire cluster with a single selectable marker. We
targeted the 25-gene cluster that produces sterigmatocystin (ST), an abundant toxin,32 for
deletion by replacing it with the Aspergillus fumigatus pyrG (AfpyrG) gene33(Table 1 and
Figure 1a). For this strategy to be successful, the flanking sequences on the transforming
molecule must undergo homologous recombination with two chromosomal sequences > 50
kb apart. The target strain carried the mutation pyrG89 which blocks growth on media
unsupplemented for pyrimidines. AfpyrG complements pyrG89, allowing growth in the
absence of added pyrimidines. To reduce non-homologous recombination, we used a strain
carrying nkuA Δ.34 To evaluate the efficiency of cluster replacement, the strain also carried
riboB2 (riboflavin requirement) and a replacement of the stcJ gene, a gene within the ST
cluster, with the A. fumigatus riboB gene (AfriboB).34 AfriboB complements riboB2 and
supports growth in the absence of riboflavin. Correct homologous recombination of the
transforming fragment with the genome would result in excision and loss of the entire ST
cluster including the AfriboB gene inserted in place of stcJ. Loss of AfriboB, in turn, results
in a riboflavin requirement. Riboflavin auxotrophy is, thus, an indication that at least the
portion of the ST cluster with the inserted AfriboB gene has been deleted. Transformation
yielded abundant AfpyrG+ transformants. We tested 118 transformants and found that 78
required riboflavin. At least a portion of the ST cluster was, thus, replaced in 66% of
transformants. We tested seven of the riboflavin-requiring transformants by diagnostic PCR
(Supplemental Figure S1) and found that the entire ST cluster had been replaced by AfpyrG
in each case. The deletion of the ST cluster was further confirmed by Southern hybrization
for one transformant (result not shown). The size of the fragment deleted was 50,096 bp and
these data, thus, reveal that even a very large SM cluster can be easily deleted by
replacement with a small DNA fragment carrying a selectable gene. They also indicated that
the procedure was efficient enough that it was not necessary to embed a selectable marker
such as AfriboB within the cluster to identify cluster deletants.
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We next deleted the emericellamide cluster35 using the same approach except that we used 1
kb flanking sequences and we did not embed a marker within the cluster. The size of the
region targeted for deletion was 37,423 bp. Five of eight transformants tested by diagnostic
PCR had correct deletions of the cluster. Deletion of the cluster was further confirmed for
one of these transformants by Southern hybridization. For clusters of this size, 1 kb flanking
sequences are, thus, perfectly adequate.
Because we have previously inserted AfpyrG into many SM clusters, we developed a second
approach that allows us to delete these clusters while recycling the AfpyrG marker so that it
can be used again (Figure 1b). AfpyrG encodes orotidine-5’-phosphate decarboxylase, a key
enzyme in pyrimidine metabolism. If 5-fluoro-orotic acid (5-FOA) is present, orotidine-5’-
phosphate decarboxylase converts it to the toxic compound 5-fluorouracil. 5-FOA can thus
be used to select for the loss of genes such as AfpyrG that encode a functional orotidine-5’-
phosphate decarboxylase.36, 37 We attempted to delete a very large (77 kb) cluster
containing the NRPS gene AN9226 (product unknown) into which we had previously
inserted AfpyrG. The transforming fragment contained approximately 2 kb of flanking DNA
from each side of the cluster but no selectable marker and the actual size of the region
targeted for deletion was 77,070 bp. Diagnostic PCR revealed that five of nine transformants
selected on 5-FOA carried the correct cluster deletion. We also deleted the emericellamide
cluster again using this approach with similar results. Since, in this procedure, AfpyrG is
removed, it can be inserted into another cluster and the process repeated to delete, in
principle, an unlimited number of clusters.
Finally, we developed a variant of the loop-out recombination procedure developed for
Aspergillus oryzae and Aspergillus sojae38 (Supplementary Figure S2). We used fusion PCR
to create the transforming fragment rapidly, rather than the more complex and time-
consuming published procedure,38 and we used AfpyrG as the selectable marker. With this
procedure we deleted the ST, emericellamide, orsellinic acid/F9775A, B,39,40 asperfuranone,
monodictyphenone41 and terrequinone42 clusters. In summary, we have developed three
approaches that allow us to delete entire SM gene clusters in A. nidulans using linear DNA
molecules created rapidly by fusion PCR. The ability to delete entire A. nidulans SM
clusters allows us to eliminate production of undesired toxins and to eliminate clusters that
might interfere with the analysis of heterologously expressed SM pathway genes. This
removes important barriers in developing A. nidulans as a production organism.
An efficient procedure for heterologous expression of SM genes in A. nidulans
The approach we have developed uses fusion PCR to amplify genes from genomic DNA of
a target fungus, place them under control of alcA(p) and fuse them into fragments that can
be used to transform A. nidulans (Figure 2). Because core SM genes such as PKS or NRPS
genes are large and difficult to amplify by PCR, we have developed a system in which we
create two (or, for very large genes, three) smaller transforming fragments that fuse by
homologous recombination in vivo during transformation resulting in reconstruction of a full
length coding sequence under control of alcA(p) (Figure 2). We use flanking sequences
from the wA locus to direct integration such that the wA gene is replaced with the
transforming fragment and this results in correct transformants having white conidia. Each
of the transforming fragments carries a selectable marker (AfpyrG and AfriboB in the
example shown) and we select for transformants that are transformed with both fragments
(i.e. they grow on media unsupplemented with pyrimidines or riboflavin). Correct
transformants are verified by diagnostic PCR.
We transfer additional genes as shown in Figure 3. In the example shown, a second gene
(Gene B) is inserted adjacent to a PKS gene that has been inserted at the wA locus. The
procedure uses fusion PCR to create a fragment that carries 1) a targeting sequence of about
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1000 bp that corresponds to the 3’ end of coding sequence and 3’ untranslated region of the
gene next to which the fragment is to be inserted (in this case the PKS), 2) alcA(p), the
coding region and 3’ untranslated region of the gene to be transferred, 3) a selectable marker
(AfpyroA in the example shown, and 4) approximately 1000 bp of wA downstream
sequence. The selectable marker and the wA downstream sequence can be fused into a
cassette that can be used for additional experiments. Integration by homologous
recombination inserts Gene B and removes AfriboB. Transformants are selected on their
ability to grow in media unsupplemented with pyridoxine, tested to determine if they require
riboflavin, and verified by diagnostic PCR. The process can be repeated for a third gene
using AfriboB and displacing AfpyroA. Since a selectable marker is recycled at each step,
that there is always a selectable marker available for the next transformation, and, in
principle, an unlimited number of genes can be transferred. An advantage of this approach is
that genes do not have to be cloned in the normal sense because they are simply amplified
from genomic DNA. The procedure is also rapid in that transforming fragments can be
constructed in two days once PCR primers have been obtained and many transforming
fragments can be constructed in parallel with one thermocycler.
One potential concern with this procedure is that since the genes that have already been
transferred and the gene on the transforming fragment are both under control of alcA(p),
homologous recombination between alcA(p) upstream of one or more of the previously
transferred genes and alcA(p) on the transforming fragment could result in the deletion of
one or more of the previously transferred genes. Such events are easily detectable by
diagnostic PCR and in our hands they do not occur frequently enough to slow progress. We
routinely test several transformants from each transformation and find that most of them are
correct. The likely reason that recombination between alcA(p) sequences is not a significant
problem is that the flanking sequences are much larger than the alcA(p) sequence (about
1000 bp vs 400 bp), and it is possible that the end sequences are more recombinogenic than
the alcA(p) sequence which is internal on the transforming fragment.
Another potential concern was that PCR amplification of large genes might result in PCR-
induced mutations that would render the genes dysfunctional. We consequently used high
fidelity DNA polymerases and screened several transformants in each case. These steps
appeared to obviate the problem although, in a few cases, we found that one transformant
among several tested did not produce a compound that its sister transformants produced.
We analyzed the PKS genes in the A. terreus genome using the Broad Institute Aspergillus
Comparative Database (http://www.broadinstitute.org/annotation/genome/
aspergillus_group/MultiHome.html) and identified genes encoding nine NR-PKSs, 16
highly-reducing PKSs (HR-PKSs), one hybrid PKS-NRPS and one partially reducing PKS.
[Designations are based on domain architectures and phylogeny (Supplementary Figure
S3)]. To determine the efficacy of our approach, we focused on NR-PKS genes. We
previously completed the elucidation of the chemical products released from all A. nidulans
NR-PKSs by replacing their promoters with alcA(p), while coexpressing accessory genes as
necessary.43 This led us to divide NR-PKSs into seven groups, based on phylogenetic
analyses, domain structures, and products released.43 Group I ∼ V NR- PKSs do not have a
C-methyltransferase (CMeT) domain. Group I NR-PKSs contain a thioesterase (TE)
releasing domain and synthesize single ring aromatic polyketides. Groups II, III, and IV
contain a thioesterase/Claisen cyclase (TE/CLC) releasing domain and synthesize multiple
ring aromatic polyketides. Group V NR-PKSs do not contain a releasing domain and the
aromatic polyketide is released by a β-lactamase-type TE (β-TE) encoded by a separate
gene. Group VI and VII are CMeT containing NR-PKSs. They synthesize single ring
benzoic acid and benzaldehyde after release by the TE (group VI) or reductive (R, group
VII) domain, respectively. When an HR-PKS gene or fatty acid synthase (FAS) genes are
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near the NR-PKS, the HR-PKS or FAS are likely to synthesize the starter unit for the NR-
PKS. Understanding the priming and releasing mechanisms of NR-PKSs gave us some
confidence that we could predict what genes might need to be co-expressed to obtain the
released NR-PKS products. We have analyzed the A. terreus NR-PKSs and placed them into
these groups (Figure 4).
We transferred each A. terreus NR-PKS gene into A. nidulans and confirmed that the
transfers were correct by diagnostic PCR (Supplementary Figure S1). Based on our previous
results and analyses,43 we expected that expression of five of the NR-PKSs would result in
product synthesis and release without co-expression of additional genes. Induction of
expression of ATEG_00145.1, ATEG_03629.1 and ATEG_03432.1 resulted in the
production of metabolites detected by liquid chromatography mass spectrometry (LC/MS)
as predicted (Figure 5). [Note: all A. terreus gene designations are from the Broad Institute
Aspergillus Comparative Database. Aspergillus nidulans genes from this database (below)
have the prefix ANID. A. nidulans genes from the Aspergillus genome database (AspGD,
www.aspgd.org) (below) have the prefix AN.] From large-scale cultures, we isolated the
products and determined their structures by spectroscopic methods. ATEG_00145.1
produced compounds 1 – 4, ATEG_03629.1 produced compound 5, and ATEG_03432.1
produced compounds 6 and 7 (Figure 4a, e, and g). Compounds 6 and 7 are new to science.
Products were not detected for ATEG_10080.1 and ATEG_07500.1. Comparisons of
ATEG_10080.1 with the highly homologous A. nidulans gene ANID_08383.1 suggested
that the correct start codon might be upstream of the annotated one (Supplementary Figure
S4). We made a new construct using the alternative start codon and transferred it into A.
nidulans. Induction of the new construct resulted in the production of a major compound 8
(Figure 4f and 5). Reannotation and expression of this gene in Aspergillus oryzae was
recently reported by another group.44
We revised the start codon for ATEG_07500.1 based on its identity/similarity (93%/96%) to
an unpublished A. terreus naphthopyrone synthase (GenBank accession no. BAB88689.1)
cloned by Watanabe and Ebizuka and transferred a construct with the new start codon into
A. nidulans. However, we were still unable to detect new products upon induction (Figure
5).
ATEG_08451.1 and ATEG_02434.1 fall into our group V and lack TE domains. For such
PKSs, β-lactamases encoded by other genes provide the activity required to release their
products.45–47 The PKS encoded by ATEG_08451.1 (which has been designated ACAS) has
been shown to produce atrochrysone (9) and its derivatives when co-incubated in vitro with
ACTE, a β-lactamase encoded by ATEG_08450.1.46 We transferred ATEG_08451.1 and
ATEG_08450.1 into A. nidulans and upon induction, atrochrysone (9) and its derivative
emodin (10) were readily detectable by HPLC-DAD-MS (Figure 4c, 5 and Supplementary
Figure S5), confirming previous results.46
We identified a putative thioesterase gene (ATEG_02438.1) near ATEG_02434.1 that might
be responsible for product release. We also deduced that the start codon of ATEG_02434.1
was probably incorrectly annotated, by comparing its predicted coding sequence with those
of homologous PKS genes from other species of Aspergillus. We transferred
ATEG_02438.1 and the reannotated ATEG_02434.1 into A. nidulans. Induction of both
genes resulted in production of several metabolites (Figure 5). However, we were unable to
identify these metabolites due to their instability. Although we have not yet attempted to
transfer additional genes, such transfers might result in products that are more stable and
amenable to analysis.
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Our analyses predicted that the two group VII NR-PKSs, ATEG_07661.1 and
ATEG_08662.1, would use precursors produced by an adjacent HR-PKS and fatty acid
synthase respectively. We transferred both ATEG_07661.1 and the adjacent HR-PKS
ATEG_07659.1 into A. nidulans and upon induction detected compound 11, an intermediate
of the asperfuranone biosynthesis pathway.48 Similarly, we created an A. nidulans strain
expressing ATEG_08662.1 and the two fatty acid synthase subunit genes adjacent to it in the
A. terreus genome, but we could not detect any metabolites upon induction (Figure 5).
In summary, the heterologous expression system we have developed has allowed us to
detect compounds produced by all but two A. terreus NR-PKSs. In these cases we may not
have identified the correct start and stop codons and it is also possible that transfer of
additional genes may be required for compound production or release.
Expression of a complete A. terreus secondary metabolite biosynthetic pathway in A.
nidulans
To test the utility of our system we wanted to determine if we could express an entire
biosynthetic pathway from A. terreus in A. nidulans. We selected the biosynthetic pathway
containing the NR-PKS ATEG_07659.1 and the HR-PKS ATEG_07661.1. As mentioned,
expression of these genes in A. nidulans resulted in production of 11, an intermediate in
asperfuranone biosynthesis. The A. nidulans asperfuranone (afo) cluster contains seven
genes48 including a transcription factor that regulates expression of the cluster. Our analysis
of genes in the vicinity of ATEG_07659.1 and ATEG_07661.1 revealed that they were
homologous to the afo genes and that the structure of the cluster mirrored the afo cluster
(Figure 6). This suggested that the ATEG_07659.1/ATEG_07661.1 cluster produces
asperfuranone or a similar compound.
We deleted the A. nidulans afo cluster [AN1029-AN1036 inclusive (=ANID_01029.1-
ANID_01036)] by replacing it with ptrA, a pyrithiamine resistance gene49 so that the
enzymes of this pathway could not interfere with the analysis of the heterologously
expressed cluster. We created strains LO6751 and LO6744 that carry the afo cluster deletion
and the transferred ATEG_07659.1 and ATEG_07661.1 genes. We sequentially transferred
the remaining four genes of the A. terreus cluster into these strains (Figure 6). Induction of
five genes resulted in production of asperfuranone (12) (Figure 7b, traces ix - xi). The
expression of a sixth gene, a putative pump homolog, did not alter asperfuranone production
(Figure 7b, trace xii). These genes thus constitute an asperfuranone biosynthetic cluster in A.
terreus. We have cultured NIH2624, the sequenced strain from which we transferred the
genes, under various conditions and have not identified asperfuranone. We have, thus, been
able to express a pathway that is normally silent in A. terreus and identify it as the
asperfuranone biosynthetic pathway. The A. nidulans asperfuranone cluster is normally
silent as well, and to obtain expression we previously had to replace the promoter of a
transcription factor gene (afoA) associated with the cluster with alcA(p) and induce its
expression. The induced expression of afoA resulted in expression of the entire cluster and
production of asperfuranone.48 We have given the genes of the A. terreus pathway
designations (Figure 6) based on homology to the A. nidulans genes.48 Thus, for example,
the A. terreus homolog of the A. nidulans afoA gene is designated AteafoA following the
convention: (http://www.aspergillus.org.uk/indexhome.htm?secure/sequence_info/
nomenclature.htm~main) and the product of this gene is AteAfoA.
We obtained a yield of 6.87 ± 0.85 mg/L of asperfuranone in the heterologous expression
strain, slightly more than we obtained in parallel experiments with the endogenous A.
nidulans afo cluster with alcA(p)afoA induced (5.63 ± 0.33 mg/L). Our heterologous
expression system, thus, gives good yields of asperfuranone and we anticipate that this will
be the case with compounds produced by other heterologously expressed clusters. We noted,
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however, that significant quantities of intermediates were present in the induced
heterologous expression strain. Our interpretation is that in the endogenous pathway, the
various genes are expressed at optimal levels to result in a single final product, whereas in
our system all genes are expressed at high levels resulting in accumulation of intermediates.
Expression of combinations of Ateafo genes allows refinement of the asperfuranone
biosynthesis pathway
Finally, we have expressed various combinations of A. terreus asperfuranone cluster genes
that have caused us to revise our proposed biosynthetic pathway for asperfuranone.48 The A.
nidulans afo cluster was deleted in all of these strains so that the genes of this cluster could
not affect our heterologous expression results. Results are shown in Figure 7. As mentioned,
expression of AteafoG and AteafoE resulted in the production of the polyketide intermediate
compound 11 (Figure 7b, traces i and ii). Since, at the onset, the order of the next three
genes in the pathway was unclear, we transferred each of them separately into an AteafoG/
AteafoE expression strain. Expression of AteafoF in the AteafoG/AteafoE expression strain
did not result in a new product, indicating that AteAfoF does not modify 11 (Figure 7b, trace
iii). Compounds 13 and 14 are spontaneously cyclized products of 11 when it is dissolved in
methanol during LC-MS analysis (Figure 8a).48 Expression of AteafoD in the AteafoG/
AteafoE expression strain resulted in the production of 16 and 17 and the disappearance of
11 suggesting that AteAfoD is the next enzyme in the pathway (Figure 7b, trace iv). The
structures of 16 and 17 both contain a hydroxyl group at C-4 (Figure 8b, for details of
structural elucidation, see supplemental data). This suggested that the function of AteAfoD
is dearomatization of the precursor 11 to generate intermediate A (Figure 8a). Compound 16
could be produced from intermediate A after cyclization and dehydration (Figure 8b). The
cyclization step is likely to be spontaneous due to the formation of the six-membered ring
hemiacetal intermediate. Moreover, the dearomatization of 11 increases the electrophilicity
of the C-1 aldehyde which could facilitate the cyclization. Compound 17 could be generated
from 16 by endogenous reductases or from intermediate A via cyclization, dehydration, and
reduction mechanisms after reduction of the C-1 aldehyde to a primary alcohol by an
unknown endogenous reductase (Figure 8b).
An unexpected result was that addition of AteafoC into the AteafoG and AteafoE expression
strain resulted in increased yields of compounds 11, 13, and 14 (Figure 7b, traces ii and v).
This suggested that AteAfoC was involved in an early step of 11 biosynthesis. Although
AteAfoC is homologous to the putative oxidoreductase CtnB,48,25 AteAfoC does contain an
esterase/lipase domain. Thus, AteAfoC might be involved in the releasing of the side chain
15 from AteAfoG or might facilitate the side chain transfer from AteAfoG to AteAfoE. To
test this hypothesis we created an AteafoG and AteafoC co-expression strain. Co-expression
of AteafoG and AteafoC resulted in the production of the side chain 15 albeit at a very low
level (∼1 mg/L, Figure 7b, trace vi). Considering the high yield of 11 (∼300 mg/L) in the
AteAfoG, E, and C coexpression strain, the low yield of 15 might indicate that the function
of AteAfoC is to facilitate the transfer of 15 from AteAfoG to AteAfoE.
As expected, adding AteafoD to the AteafoG, AteafoE and AteafoC expression strain
resulted in increased yields of intermediates 16 and 17 in comparison with the AteafoG,
AteafoE, and AteafoD expressing strain (Figure 7b, traces iv and vii). This led us to test
whether we could further increase the yield by expressing two copies of AteafoC. Indeed,
the yield of 16 and 17 in the strain with two copies of AteafoC was about 1.5 fold higher
than in the strain that contained only one copy of AteafoC (Figure 6B, traces vii and viii).
We were able to purify minor metabolites 18 and 19, which are shunt products, from the
strain expressing two copies of AteafoC. Compounds 17, 18 and 19 are new to science. This
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highlights an advantage of our marker recycling system, that we are able to increase the
metabolite yield simply by increasing the gene copy number of rate limiting enzymes.
By adding AteafoF into the AteafoG, AteafoE, AteafoC and AteafoD expression strain, as
mentioned, we successfully reconstituted the entire AteAfo pathway in A. nidulans, to
produce asperfuranone (12, Figure 7b, trace ix) (in effect assembling our own asperfuranone
operon). Thus, AfeAfoF functions as a C-8 oxygenase to generate 20. Introducing the
hydroxyl group at C-8 prevented the C-8, C-9 enol formation, thus, suppressing the
formation of a six-membered ring hemiacetal intermediate. After cyclization and
dehydration of 20 via a five-membered ring hemiacetal intermediate, 21 could be generated
(Figure 8a). Since we did not add a reductase into the asperfuranone (12) producing strain,
the conversion from 21 to 12 is likely to be catalyzed by an endogenous reductase. The afo
and Ateafo clusters do contain a putative dehydrogenase or reductase (AN1030 and
ATEG_07665.1). The fact that deletion of AN1030 did not alter the yield of asperfuranone48
suggested that, if this gene is indeed involved in the transformation from 21 to 12, the
function can be compensated by an unknown endogenous reductase encoded by a gene
somewhere else in the genome.
To see if the position of the genes in the newly constructed pathway was important, we
created two additional strains in which the order of AteafoC, AteafoD and AtoafoF were
different, making a total of three strains in which the order of these genes was different. All
three strains produced nearly identical metabolite profiles (Figure 7b, traces ix - xi),
suggesting that position effects are minimal or non-existent and that we can sequentially
integrate all putative biosynthetic genes from an unknown gene cluster into our host without
considering the location of each gene. It is interesting to note that, as mentioned, the HPLC
profile did not change obviously after coexpression of the putative efflux pump AteafoB
with the AteafoC-G expression strain (Figure 7b, traces x and xii). Thus, the function of
AteAfoB or its homolog AfoB is unlikely to be a transporter of the identified metabolites in
the afo biosynthetic pathway. Deletion of afoB resulted in a decreased production of
asperfuranone (12),48 however, so AfoB does play some role in asperfuranone production in
A. nidulans when the afo pathway genes are under control of their normal promoters. This
raises the possibility that AfoB has a function in regulation of the pathway, but the function
of AfoB remains elusive and awaits further study.
From results of our reconstitution study, our original hypothesis, that the function of AfoD is
to oxidize the C-8 benzylic carbon of 11 to become intermediate B, needs to be revised
(Figure 8A).48 Davison et al.50 and Zabala et al.51 recently reported that the function of the
AfoD homologs, TroB from Talaromyces stipitatus and AzaE from Aspergillus niger is
dearomatization of the aromatic product released from an NR-PKS. Our data support and
confirm their results. Moreover, Zabala et al. speculated that AfoC might facilitate the
transfer of 15 from AfoG to AfoE.51 In vivo evidence from our heterologous expression
studies support their hypothesis.
Prospects for expressing additional SM genes
Our system for expressing SM genes from other fungi in A. nidulans is rapid, robust and
flexible. It has allowed us to express and purify the products of six NR-PKS genes of A.
terreus, to identify two compounds new to science and to assemble and express an entire A.
terreus biosynthetic pathway, which resulted in the identification of the A. terreus
asperfuranone biosynthetic cluster, a previously cryptic cluster. Importantly, our approach
bypasses normal regulatory mechanisms. Arguably, we understand SM cluster regulation
better in A. nidulans than in any other fungus, but we still do not understand how to activate
most SM clusters.43 While we might be able to transfer intact clusters from other fungi into
A. nidulans by other mechanisms, this would be only a starting point for obtaining
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expression. In our system, by placing each gene under control of alcA(p), we control
expression. Glucose represses alcA(p) and if transferred genes produce compounds toxic to
A. nidulans they will not be produced as long as glucose is present so transformants will
survive. We can then induce alcA(p) and produce the toxic compounds, at least transiently.
The alcA promoter can drive gene expression at high levels,30, 52 resulting in good product
yields. For very large clusters, AlcR, the activator of alcA(p), might be limiting, but this can
be remedied by expressing alcR from a high level constitutive promoter.53 In principle,
other promoters can also be used with our approach.
Our approach is most obviously useful for expressing and identifying the products released
by NR-PKS from diverse species of Aspergillus and expressing relatively small SM gene
clusters or portions of larger clusters. There is no obvious technical barrier to transferring all
the genes of large clusters into A. nidulans, however, and our approach is quite rapid.
Transferral of a gene and verification takes about two weeks and transferral of genes of
many clusters can be carried out in parallel. However, as the number of transferred genes
increases the likelihood of failed expression due to incorrect annotation increases. This
limitation will be reduced as annotation procedures improve. Our approach requires very
little DNA and if an accurate sequence can be obtained and annotated correctly, it can, in
theory, be even used to express SM clusters from fungi that are currently not culturable.
In principle, our approach should work for clusters containing HR-PKS, NRPSs and terpene
synthases or cyclases and we are in the process of testing the efficacy of this approach for
these enzymes. It is also likely that A. nidulans can be used as a heterologous host for
expression of SM genes from genera of fungi other than Aspergillus. However, given the
fact that there are approximately 250 known species of Aspergillus54 and each species likely
has roughly 10 NR-PKSs, even if our approach works only for relatively small NR-PKS
clusters in Aspergillus spp. it has the potential to unlock a substantial storehouse of natural
products.
Conclusion
We have developed an efficient system for heterologous expression of fungal secondary
metabolism genes in Aspergillus nidulans. This system includes methods for deletion of
entire A. nidulans secondary metabolite gene clusters to eliminate production of the most
abundant A. nidulans SMs including important toxins. This reduces the SM background and
facilitates detection and purification of the products of heterologously-expressed clusters. It
also includes a method for amplifying secondary metabolism genes from other fungi,
placing them under the control of a regulatable promoter and inserting the genes at a target
locus in A. nidulans. Our system incorporates selectable marker recycling so that an
unlimited number of genes can be transferred into, and expressed in, A. nidulans. We have
used this system to obtain compound production and release from six NR-PKSs of A. terreus
and we have identified the products. We have transferred and expressed all the genes of a
cryptic cluster from A. terreus and have found that the cluster produces asperfuranone. In
addition, by expressing the genes in the asperfuranone cluster in various combinations and




Strains used in this study are listed in Supplementary Tables S1 and S2.
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Transforming fragments were generated by fusion PCR essentially as described.34, 55, 56 To
reduce the frequency of PCR-induced mutations, we used high-fidelity DNA polymerases.
For fragments < 2kb, we generally used AccuPrime Pfx DNA polymerase (Invitrogen). For
larger fragments we used KOD DNA polymerase (EMD Biosciences) or Phusion DNA
polymerase (New England Biolabs or Thermo) and we used these enzymes for fusion PCR
as well. Ramp rates were as previously described,34, 55, 56 but for AccuPrime Pfx the
annealing temperature was Tm (for the lowest melting temperature primer) − 5°C (Tm
calculated as previously described55). For KOD and Phusion DNA polymerases the
annealing temperature was Tm + 2°C and the extension rate was 30 sec/kilobase of expected
product. Similarly, the constructs used for cluster deletions were made by fusion PCR with
AccuPrime Pfx DNA polymerase used for amplification of fragments < 2kb and KOD or
Phusion DNA polymerases used for larger fragments and for fusion PCR.
Production of protoplasts and transformations were carried out as described34, 55, 56 except
that, because of the discontinuance of production of VinoFlow FCE, in later experiments
VinoTaste Pro (Novo) was used at a final concentration of 100 mg/ml for protoplasting.56
For selection of transformants on 5-FOA, 1 mg/ml 5-FOA, 10 mM uridine and 1mg/ml
uracil were added to selection plates. Selection for cluster loop outs on 5-FOA was as
previously described.37
Diagnostic PCR was carried out as described57 using Platinum Taq DNA polymerase
(Invitrogen) or OneTaq Hot Start Quickload (New England Biolabs). Diagnostic PCR
strategies are shown in Supplemental Figure S1.
Fermentation and LC/MS analysis
For alcA(p) induction, 3 × 107 spores were grown in 30 ml liquid LMM medium (15 g/l
lactose, 6g/l NaNO3, 0.52g/l KCl, 0.52g/l MgSO4 7H2O, 1.52g/l KH2PO4, 1 ml/l trace
elements solution) in 125 ml flasks at 37°C with shaking at 180 rpm and supplemented with
riboflavin (2.5 mg/l), or pyridoxine (0.5 mg/l) when necessary. Cyclopentanone was added
to the medium at a final concentration of 10 mM 18 hr after inoculation. Culture medium
was collected 48 hr after cyclopentanone induction by filtration and extracted with the same
volume of EtOAc. In order to extract most acidic phenolic compounds, the water layer was
extracted with the same volume of EtOAc after acidification (pH = 2). EtOAc extract was
then evaporated by TurboVap LV (Caliper LifeSciences). The crude extracts were re-
dissolved in 0.5 ml of DMSO:MeOH (1:4) and 10 µl was injected for LC-DAD-MS analysis
as described previously.58 Details for large-scale purifications of compounds for each strain
and compound identification are given in the Supplemental Information as are spectral data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Two strategies for deletion of SM gene clusters. a. The target strain is transformed with a
fragment containing the A. fumigatus pyrG gene (AfpyrG) flanked by two 2 kb sequences
that are > 50 kb apart in the genome, one upstream of the ST cluster and one downstream.
The fragment is constructed by fusion PCR34,55 and the flanking fragments are amplified
from genomic DNA using primers designed from genome sequence data. Upon
transformation, homologous recombination results in the replacement of the entire ST
cluster with AfpyrG. AfriboB was previously inserted in the cluster and replacement of the
cluster with AfpyrG results in removal of AfriboB and this causes riboflavin auxotrophy. b.
The AfpyrG gene was previously inserted into the target cluster by transformation. The
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transforming fragment is composed of two sequences, one from just upstream of the cluster
and the other from just downstream of the cluster. They are amplified from genomic DNA
and joined by fusion PCR. Upon transformation, homologous recombination results in
excision of the target cluster including AfpyrG. Transformants in which AfpyrG has been
excised are selected on 5-FOA. AfpyrG can be subsequently reused as a selectable marker.
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Transferral of a PKS gene into A. nidulans. A portion of a PKS gene extending from the
start codon is amplified from genomic DNA of the target organism and joined by fusion
PCR to a cassette containing ≈ 1000 bp of flanking sequence upstream of the A. nidulans
wA (white conidia) gene, AfpyrG and alcA(p). A 3’ portion of the target PKS gene
overlapping by approximately 1 kb with the 5’ portion and extending approximately 100 bp
downstream of the termination codon is fused to a cassette containing AfriboB34 and
approximately 1000 bp wA downstream flanking sequence. The fusion PCR products are
co-transformed into the target strain, LO4389. LO4389 has green conidia and carries
nkuAΔ, a deletion of the ST cluster and three selectable markers, [pyrG89 (pyrimidine
auxotrophy), riboB2 (riboflavin auxotrophy), and pyroA4 (pyridoxine auxotrophy)]. Upon
transformation the two fragments undergo homologous recombination with the wA flanking
sequences and with each other, resulting in replacement of the wA gene with a full-length
coding sequence of the PKS under control of alcA(p). Transformants are selected for both
pyrimidine and riboflavin prototrophy and correct transformants have white conidia. The
procedure works equally well for NRPS and other large genes.
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Transferral of additional genes with marker recycling. Using four piece fusion PCR, we
create a transforming fragment containing approximately 1000 bp from the C-terminus of
the PKS already inserted (approximately 900 bp of coding sequence plus 100 bp of 3’
untranslated region), alcA(p), the coding sequence of the gene of interest plus 100 bp of 3’
untranslated region, AfpyroA, a selectable marker34, and 1000 bp of wA downstream
sequence. Transformation with this fragment inserts the gene, under the control of alcA(p),
and it evicts AfriboB allowing it to be used as a selectable marker for the next
transformation. In principle, recombination between alcA(p) on the transforming fragment
and alcA(p) upstream of the PKS could cause deletion of the PKS, but in practice this event
did not occur frequently enough to hinder progress. To add a third gene the process shown in
b is repeated except that AfriboB is used as a selectable marker and AfpyroA is excised
upon transformation. The process can be repeated over and over.
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Aromatic polyketides identified from heterologous expression of A. terreus NR-PKSs
together with accessory genes in the engineered A. nidulans host. The domain structure of
each NR-PKS is shown as well as the product released. Defining features of the groups are
discussed in.43
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Total scan HPLC profiles of metabolites extracted from the culture medium before or after
acidification of A. nidulans strains expressing A. terreus genes under the control of alcA(p).
The genes expressed are listed above each trace. The numbering of the peaks corresponds to
compounds shown in Figure 4. Peaks that are also present in other strains are marked by a
black triangle (▼) and are considered not to be specific to the expressed genes. Peaks that
are specifically present in induced strains but are not structurally elucidated due to low yield
or pool stability are marked with a dagger (†). ▽: Lumichrome, a degraded product from
riboflavin. *: Transferred genes with a revised start site.
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Gene organization of the A. nidulans afo and A terreus Ateafo clusters.
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The A. terreus asperfuranone (Ateafo) gene cluster assembled in A. nidulans with each gene
placed under control of the alcA promoter. Total scan HPLC profiles of metabolites
extracted from the culture media of A. nidulans strains expressing A. terreus afo cluster
genes under the control of alcA(p). The numbering of the peaks corresponds to compounds
shown in Figure 8. The Ateafo genes expressed are listed above each trace. (i) is the trace
for the control strain. *Unstable metabolites that have different chromophores from those
compounds identified in this study.
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a. A revised biosynthetic pathway of asperfuranone from reconstitution studies. b. Proposed
biotransformation from intermediate A to 16 and 17.
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Table 1
Promoters and selectable genes used in this study.
Description Reference(s)
alcA(p) The promoter from the A. nidulans alcA (alcohol dehydrogenase) gene. The promoter is strongly repressed by
glucose and induced to various levels by alcohols and other compounds. 30, 31
AfpyrG The Aspergillus fumigatus homolog of the A. nidulans pyrG gene. pyrG encodes orotidine-5’-phosphate
decarboxylase. An A. nidulans pyrG mutation (pyrG89) renders the enzyme dysfunctional and causes a
requirement for uridine or uracil. AfpyrG complements pyrG89 restoring growth in the absence of uridine or
uracil.
33
AfriboB The A. fumigatus homolog of the A. nidulans riboB gene. riboB2 is a mutation that causes a requirement for
riboflavin. AfriboB complements riboB2, restoring growth in the absence of riboflavin. 34
AfpyroA AfpyroA is the A. fumigatus homolog of the A. nidulans pyroA gene. pyroA4 is a mutation that causes a
requirement for pyridoxine. AfpyroA compements pyroA4, restoring growth in the absence of pyridoxine. 34
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